10 Results for "

177Lu radiolabeling

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "177Lu radiolabeling" in MCE Product Catalog:

Tyr3-Octreotate
Tyr3-Octreotate
0 Images
製品番号: HY-P10239
CAS 番号: 302794-43-0
Target:  

Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs)

研究分野:  

Cancer

Tyr3-Octreotate is a ligand for somatostatin receptor subtype 2 (sst2), with an IC50 value of 1.3 nM against sst2 when labeled with [ 111In-DTPA], and an IC50 value of 1.6 nM against sst2 when labeled with [ 90Y-DOTA]. Radiolabeled Tyr3-Octreotate generates cell-associated radioactivity, and acts as both a tumor growth inhibitor and a tumor cytotoxic agent. When radiolabeled with 177Lu or 90Y, Tyr3-Octreotate serves as a peptide receptor radionuclide therapy (PRRT) analog. Tyr3-Octreotate can be used in studies related to pancreatic tumors .
loading...
    loading...
View All Sizes
ErbB-2-binding peptide-1
ErbB-2-binding peptide-1
0 Images
製品番号: HY-P4082
CAS 番号: 562791-56-4
別名: LTVSPWY
Target:  

EGFR Radionuclide-Drug Conjugates (RDCs)

研究分野:  

Cancer

ErbB-2-binding peptide-1 (LTVSPWY) is a HER2 receptor-binding peptide. ErbB-2-binding peptide-1 can be conjugated with nuclear cross-linked micelles loaded with Doxorubicin (HY-15142A). ErbB-2-binding peptide-1 can also be radiolabeled to form 177Lu-DOTA-LTVSPWY. ErbB-2-binding peptide-1 is conjugated with antisense oligonucleotides. ErbB-2-binding peptide-1 can be used in research related to HER2-positive breast cancer and ovarian cancer .
loading...
    loading...
View All Sizes
FAPI-mFS
FAPI-mFS
0 Images
製品番号: HY-164725
CAS 番号: 3023869-94-2
Target:  

Radionuclide-Drug Conjugates (RDCs) FAP

研究分野:  

Cancer

FAPI-mFS is a selective fibroblast activation protein (FAP) inhibitor with an IC50 of 0.0014 μM against human FAP. Through its covalent binding property with FAP, FAPI-mFS enhances its uptake and retention time in cancer cells. When radiolabeled with 68Ga, FAPI-mFS serves as a PET/CT imaging agent with superior tumor-to-background tissue contrast and lesion detection capability. When radiolabeled with 177Lu or 225Ac, FAPI-mFS induces tumor regression and inhibition in preclinical models. FAPI-mFS can be used in studies related to cancer and radionuclide-conjugated drugs (RDC) .
loading...
    loading...
View All Sizes
PSMA-D5
PSMA-D5
0 Images
製品番号: HY-P10781
CAS 番号: 3056440-83-3
Target:  

Radionuclide-Drug Conjugates (RDCs) PSMA

研究分野:  

Cancer

PSMA-D5 has a binding affinity for PSMA with a Ki of 0.21 nM and can be used for PSMA tracing after radiolabeling. PSMA-D5 ([68Ga]-labeled) contains a DOTA chelator, allowing convenient labeling with therapeutic radionuclides such as 177Lu and 225Ac. PSMA-D5 ([68Ga]-labeled) shows excellent pharmacokinetic properties, exhibiting remarkable tumor uptake in 22Rv1 tumors . PSMA-D5 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
View All Sizes
DOTA Conjugated JM#21 derivative 7
DOTA Conjugated JM#21 derivative 7
0 Images
製品番号: HY-P10444
CAS 番号: 3033865-40-3
Target:  

Radionuclide-Drug Conjugates (RDCs) CXCR

研究分野:  

Cancer

DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
View All Sizes
BQ7876
BQ7876
0 Images
製品番号: HY-P10743
Target:  

Radionuclide-Drug Conjugates (RDCs) PSMA

研究分野:  

Cancer

BQ7876 is a probe targeting prostate-specific membrane antigen (PSMA) that contains a DOTA chelator. BQ7876, after being radiolabeled with radionuclide (177Lu), functions in both radionuclide imaging and tumor cell destruction by specifically binding to PSMA. BQ7876 shows potential for research in the field of metastatic castration-resistant prostate cancer (mCRPC) . BQ7876 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
View All Sizes
AKIR001
AKIR001
0 Images
製品番号: HY-P991922
Target:  

Fc Receptor (FcR) Complement System Radionuclide-Drug Conjugates (RDCs)

研究分野:  

Cancer

AKIR001 is a high-affinity human IgG1 antibody targeting CD44v6. AKIR001 carries LALA-silencing mutations in its FcγR-binding domain to reduce FcγR and C1q interactions, minimizing tissue interactions and limiting CDC and ADCC risks. [ 177Lu] radiolabeled AKIR001, namely [ 177Lu]Lu-AKIR001, has anticancer activity against epidermoid carcinoma .
loading...
    loading...
View All Sizes
CTB006
CTB006
0 Images
製品番号: HY-P992340

Target:  

Radionuclide-Drug Conjugates (RDCs) TNF Receptor

研究分野:  

Cancer

CTB006 is a monoclonal antibody targeting a humanized chimeric recombinant anti-DR5. CTB006 specifically binds to and activates DR5, thereby inducing tumor cell apoptosis, inhibiting tumor growth and reducing tumor drug resistance. 177Lu-radiolabeled CTB006 can deliver targeted radiotherapy to tumor cells; while 89Zr- or 177Lu-labeled CTB006 can serve as a PET/CT imaging agent for detecting DR5 expression levels in preclinical tumor models and screening cancers with DR5 overexpression. CTB006 can be applied to research related to gastrointestinal cancer, colorectal cancer and other solid tumors .
loading...
    loading...
View All Sizes
NYM074
NYM074
0 Images
製品番号: HY-183374
Target:  

Carbonic Anhydrase Radionuclide-Drug Conjugates (RDCs)

研究分野:  

Cancer

NYM074 is a carbonic anhydrase IX (CAIX) ligand. NYM074 binds specifically to human CAIX to enable targeted radionuclide delivery. NYM074 supports dual radiolabeling with 68Ga for positron emission tomography (PET) imaging and 177Lu for radionuclide applications. NYM074 can be used for the research of clear cell renal cell carcinoma .
loading...
    loading...
View All Sizes
CD73-IN-22
CD73-IN-22
0 Images
製品番号: HY-181919
Target:  

CD73 Radionuclide-Drug Conjugates (RDCs)

研究分野:  

Cancer

CD73-IN-22 (Compound HX-6) is a non-nucleoside CD73 inhibitor with an IC50 of 0.07 μM. When radiolabeled with 68Ga, CD73-IN-22 acts as a PET radiotracer for detecting CD73 expression. When radiolabeled with 177Lu, CD73-IN-22 exhibits anticancer activity against colorectal adenocarcinoma. CD73-IN-22 is applicable to research related to colon adenocarcinoma and breast cancer .
loading...
    loading...
View All Sizes
Assay Types